Hirte H, Clark D A
Ontario Cancer Treatment and Research Foundation, Hamilton Regional Cancer Centre, Ontario, Canada.
Cancer Immunol Immunother. 1991;32(5):296-302. doi: 10.1007/BF01789047.
The effect of cell-free ascitic fluid from patients with epithelial ovarian carcinoma on the generation of lymphokine-activated killer cells (LAK) was compared to the activity generated in control medium containing 10% fetal bovine serum, using Daudi target cells. Samples of ascitic fluid from nine different patients tested inhibited LAK generation. Suppressive activity was evident as early as 24 h of incubation in the presence of ascitic fluid and increasing suppression developed with prolonged exposure. Suppression was concentration-dependent, present at 10%-20% and increasing with concentrations up to 80%. The suppressive effect of ascitic fluid was only partially reversed on increasing the concentration of interleukin-2 (IL-2) from 10 units to 1000 units/ml. Activated LAK appeared to maintain the majority of their activity on further culture in ascitic fluid in the presence of IL-2 but further enhancement of lytic activity was prevented. Fractionation of a suppressive sample by HPLC, using 0.1 M KCl/acetic acid buffer pH 2.6, revealed that the dominant peak of suppressive activity eluted at 25 kDa; with pH 7.0 TRIS-buffered saline, most of the activity was lost on the column. Antibody neutralization studies of the 25-kDa suppressive peak as well as on whole ascitic fluid have revealed that transforming growth factor beta (TGF beta) is the major suppressive factor present in ascitic fluid. Factors that suppress LAK generation in vitro were present in all samples tested. The effect on the lytic activity of activated LAK cells was minimal. This suggests that, in the clinical setting, the greatest impact would be achieved by activating LAK cells ex vivo and subsequently transferring them to the peritoneal cavity in the presence of IL-2 rather than by attempting to generate them in situ by injecting IL-2 into the peritoneal cavity. However, reversal of TGF beta-mediated suppression in situ may be necessary to allow local proliferation of LAK cells to achieve an effective killer-to-target ratio.
采用Daudi靶细胞,将上皮性卵巢癌患者的无细胞腹水对淋巴因子激活的杀伤细胞(LAK)生成的影响与含10%胎牛血清的对照培养基中产生的活性进行了比较。检测的9名不同患者的腹水样本均抑制LAK生成。早在腹水存在下孵育24小时就明显出现抑制活性,且随着暴露时间延长抑制作用增强。抑制作用呈浓度依赖性,在10% - 20%时出现,且随着浓度增加至80%而增强。将白细胞介素-2(IL - 2)浓度从10单位/毫升增加到1000单位/毫升时,腹水的抑制作用仅部分逆转。在IL - 2存在下,活化的LAK细胞在腹水中进一步培养时似乎能保持其大部分活性,但溶细胞活性的进一步增强受到抑制。使用pH 2.6的0.1M KCl/乙酸缓冲液通过高效液相色谱法对一个抑制性样本进行分级分离,结果显示抑制活性的主峰在25 kDa处洗脱;使用pH 7.0的TRIS缓冲盐水时,大部分活性在柱上丧失。对25 kDa抑制峰以及整个腹水进行抗体中和研究表明,转化生长因子β(TGFβ)是腹水中存在的主要抑制因子。在所有测试样本中均存在体外抑制LAK生成的因子。对活化的LAK细胞溶细胞活性的影响最小。这表明,在临床环境中,通过在体外激活LAK细胞并随后在IL - 2存在下将其转移至腹腔,而非通过向腹腔注射IL - 2试图在原位生成LAK细胞,可能会取得最大效果。然而,可能有必要原位逆转TGFβ介导的抑制作用,以使LAK细胞局部增殖以实现有效的杀伤细胞与靶细胞比例。